Simultaneous onset of haematological malignancy and COVID: an Epicovideha survey

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013479" target="_blank" >RIV/00023736:_____/22:00013479 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/22:E0109945 RIV/65269705:_____/22:00076602 RIV/00064173:_____/22:43924354 RIV/00098892:_____/22:10157295 and 3 more
Result on the web
<a href="https://doi.org/10.3390/cancers14225530" target="_blank" >https://doi.org/10.3390/cancers14225530</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers14225530" target="_blank" >10.3390/cancers14225530</a>

Result language
angličtina
Original language name
Simultaneous onset of haematological malignancy and COVID: an Epicovideha survey
Original language description
The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)